Extended tumor control after dendritic cell vaccination with low-dose cyclophosphamide as adjuvant treatment in patients with malignant pleural mesothelioma

American Journal of Respiratory and Critical Care Medicine

Volumn 193, Issue 9, 2016, Pages 1023-1031

  Cornelissen, Robin ^a   Hegmans, Joost P J J ^a   Maat, Alexander P W M ^a   Kaijen Lambers, Margaretha E H ^a   Bezemer, Koen ^a   Hendriks, Rudi W ^a   Hoogsteden, Henk C ^a   Aerts, Joachim G J V ^a,b  

^a ERASMUS MC CANCER INSTITUTE   (Netherlands)

^b AMPHIA HOSPITAL   (Netherlands)

Author keywords

Immunosuppression; Immunotherapy; Pleurectomy decortication; Regulatory T cell; Tumor microenvironment

Indexed keywords

CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; DENDRITIC CELL VACCINE; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; PEMETREXED; IMMUNOSUPPRESSIVE AGENT; PHARMACEUTICAL VEHICLES AND ADDITIVES;

ABDOMINAL PAIN; ADULT; AGED; ARTICLE; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER CONTROL; CANCER IMMUNIZATION; CANCER IMMUNOTHERAPY; CANCER SURVIVAL; CARDIOMYOPATHY; CLINICAL ARTICLE; CONSOLIDATION CHEMOTHERAPY; CYTOREDUCTIVE SURGERY; DEPRESSION; DIARRHEA; DRUG EFFICACY; DRUG PULSE THERAPY; DRUG SAFETY; DRUG TOLERABILITY; DYSPNEA; ERYTHEMA; FATIGUE; FEASIBILITY STUDY; FEMALE; FEVER; HUMAN; HUMAN CELL; LETHARGY; LOCAL SKIN REACTION; LOW DRUG DOSE; LYMPHOCYTE COUNT; MALE; METRONOMIC DRUG ADMINISTRATION; MIDDLE AGED; MULTIPLE CYCLE TREATMENT; NAUSEA; OVERALL SURVIVAL; PERIPHERAL BLOOD MONONUCLEAR CELL; PLEURA MESOTHELIOMA; PRIORITY JOURNAL; RASH; REGULATORY T LYMPHOCYTE; SKIN INDURATION; THORAX PAIN; THORAX RADIOGRAPHY; TUMOR GROWTH; TUMOR IMMUNITY; DENDRITIC CELL; IMMUNOLOGY; IMMUNOTHERAPY; LUNG NEOPLASMS; MESOTHELIOMA; MULTIMODALITY CANCER THERAPY; PLEURA; PROCEDURES; TREATMENT OUTCOME; VACCINATION;

ADJUVANTS, PHARMACEUTIC; ADULT; AGED; COMBINED MODALITY THERAPY; CYCLOPHOSPHAMIDE; DENDRITIC CELLS; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; IMMUNOTHERAPY; LUNG NEOPLASMS; MALE; MESOTHELIOMA; MIDDLE AGED; PLEURA; T-LYMPHOCYTES, REGULATORY; TREATMENT OUTCOME; VACCINATION;

EID: 84988915207     PISSN: 1073449X     EISSN: 15354970     Source Type: Journal    
DOI: 10.1164/rccm.201508-1573OC     Document Type: Article

References (33)

1. Nakas A, von Meyenfeldt E, Lau K, Muller S, Waller D. Long-term survival after lung-sparing total pleurectomy for locally advanced (International Mesothelioma Interest Group Stage T3-T4) non-sarcomatoid malignant pleural mesothelioma. Eur J Cardiothorac Surg 2012;41: 1031-1036.
2. Linton A, Pavlakis N, O'Connell R, Soeberg M, Kao S, Clarke S, Vardy J, van Zandwijk N. Factors associated with survival in a large series of patients with malignant pleural mesothelioma in New South Wales. Br J Cancer 2014;111: 1860-1869.
3. Baumann F, Flores E, Napolitano A, Kanodia S, Taioli E, Pass H, Yang H, Carbone M. Mesothelioma patients with germline BAP1 mutations have 7-fold improved long-term survival. Carcinogenesis 2015;36: 76-81.
4. Cornelissen R, HeuversME,Maat AP, Hendriks RW, Hoogsteden HC, Aerts JGJV, Hegmans JPJJ. New roads open up for implementing immunotherapy in mesothelioma. Clin Dev Immunol 2012;2012: 927240.
5. Hegmans JP, Veltman JD, Lambers ME, de Vries IJM, Figdor CG, Hendriks RW, Hoogsteden HC, Lambrecht BN, Aerts JG. Consolidative dendritic cell-based immunotherapy elicits cytotoxicity against malignant mesothelioma. Am J Respir Crit Care Med 2010; 181: 1383-1390.
6. Hegmans JP, Aerts JG. Immunomodulation in cancer. Curr Opin Pharmacol 2014;17: 17-21.
7. Hegmans JPJJ, Hemmes A, Hammad H, Boon L, Hoogsteden HC, Lambrecht BN. Mesothelioma environment comprises cytokines and T-regulatory cells that suppress immune responses. Eur Respir J 2006;27: 1086-1095.
8. Ireland DJ, Kissick HT, Beilharz MW. The role of regulatory T cells in mesothelioma. Cancer Microenviron 2012;5: 165-172.
9. Ghiringhelli F, Menard C, Puig PE, Ladoire S, Roux S, Martin F, Solary E, Le Cesne A, Zitvogel L, Chauffert B. Metronomic cyclophosphamide regimen selectively depletes CD41CD251 regulatory T cells and restores T and NK effector functions in end stage cancer patients. Cancer Immunol Immunother 2007;56: 641-648.
10. Kan S, Hazama S, Maeda K, Inoue Y, Homma S, Koido S, Okamoto M, Oka M. Suppressive effects of cyclophosphamide and gemcitabine on regulatory T-cell induction in vitro. Anticancer Res 2012;32: 5363-5369.
11. Veltman JD, Lambers MEH, van Nimwegen M, de Jong S, Hendriks RW, Hoogsteden HC, Aerts JGJV, Hegmans JPJJ. Low-dose cyclophosphamide synergizes with dendritic cell-based immunotherapy in antitumor activity. J Biomed Biotechnol 2010; 2010: 798467.
12. Aerts JG, Cornelissen R, Lambers MEH, Hoogsteden HC, Hegmans JPJJ. Dentritic cell based immunotherapy in combination with metronomic cyclophosphamide in patients with mesothelioma. Boston: IMig; 2012.
13. Byrne MJ, Nowak AK. Modified RECIST criteria for assessment of response in malignant pleural mesothelioma. Ann Oncol 2004;15: 257-260.
14. Ceresoli GL, Zucali PA, De Vincenzo F, Gianoncelli L, Simonelli M, Lorenzi E, Ripa C, Giordano L, Santoro A. Retreatment with pemetrexed-based chemotherapy in patients with malignant pleural mesothelioma. Lung Cancer 2011;72: 73-77.
15. Zucali PA, Simonelli M, Michetti G, Tiseo M, Ceresoli GL, Collovà E, Follador A, Lo Dico M, Moretti A, De Vincenzo F, et al. Secondline chemotherapy in malignant pleural mesothelioma: Results of a retrospective multicenter survey. Lung Cancer 2012;75: 360-367.
16. Bearz A, Talamini R, Rossoni G, Santo A, de Pangher V, Fasola G, Rosetti F, Favaretto A, Gregorc V, Berretta M, et al. Re-challenge with pemetrexed in advanced mesothelioma: A multi-institutional experience. BMC Res Notes 2012;5: 482.
17. Treasure T, Utley M. Ten traps for the unwary in surgical series: A case study in mesothelioma reports. J Thorac Cardiovasc Surg 2007;133: 1414-1418.
18. Bovolato P, Casadio C, Billè A, Ardissone F, Santambrogio L, Ratto GB, Garofalo G, Bedini AV, Garassino M, Porcu L, et al. Does surgery improve survival of patients with malignant pleural mesothelioma? A multicenter retrospective analysis of 1365 consecutive patients. J Thorac Oncol 2014;9: 390-396.
19. Broomfield S, Currie A, van der Most RG, Brown M, van Bruggen I, Robinson BWS, Lake RA. Partial, but not complete, tumor-debulking surgery promotes protective antitumor memory when combined with chemotherapy and adjuvant immunotherapy. Cancer Res 2005;65: 7580-7584.
20. Alfaro C, Perez-Gracia JL, Suarez N, Rodriguez J, Fernandez de Sanmamed M, Sangro B, Martin-Algarra S, Calvo A, Redrado M, Agliano A, et al. Pilot clinical trial of type 1 dendritic cells loaded with autologous tumor lysates combined with GM-CSF, pegylated IFN, and cyclophosphamide for metastatic cancer patients. J Immunol 2011;187: 6130-6142.
21. Ge Y, Domschke C, Stoiber N, Schott S, Heil J, Rom J, Blumenstein M, Thum J, Sohn C, Schneeweiss A, et al. Metronomic cyclophosphamide treatment in metastasized breast cancer patients: Immunological effects and clinical outcome. Cancer Immunol Immunother 2012;61: 353-362.
22. Ellebaek E, Engell-Noerregaard L, Iversen TZ, Froesig TM, Munir S, Hadrup SR, Andersen MH, Svane IM. Metastatic melanoma patients treated with dendritic cell vaccination, interleukin-2 and metronomic cyclophosphamide: Results from a phase II trial. Cancer Immunol Immunother 2012;61: 1791-1804.
23. Chu CS, Boyer J, Schullery DS, Gimotty PA, Gamerman V, Bender J, Levine BL, Coukos G, Rubin SC, Morgan MA, et al. Phase I/II randomized trial of dendritic cell vaccination with or without cyclophosphamide for consolidation therapy of advanced ovarian cancer in first or second remission. Cancer Immunol Immunother 2012;61: 629-641.
24. Sistigu A, Viaud S, Chaput N, Bracci L, Proietti E, Zitvogel L. Immunomodulatory effects of cyclophosphamide and implementations for vaccine design. Semin Immunopathol 2011;33: 369-383.
25. Calabrò L, Morra A, Fonsatti E, Cutaia O, Amato G, Giannarelli D, Di Giacomo AM, Danielli R, Altomonte M, Mutti L, et al. Tremelimumab for patients with chemotherapy-resistant advanced malignant mesothelioma: An open-label, single-arm, phase 2 trial. Lancet Oncol 2013;14: 1104-1111.
26. Wing JB, Ise W, Kurosaki T, Sakaguchi S, Regulatory T cells control antigen-specific expansion of Tfh cell number and humoral immune responses via the coreceptor CTLA-4. Immunity 2014;41: 1013-1025.
27. Noy R, Pollard JW. Tumor-associated macrophages: From mechanisms to therapy. Immunity 2014;41: 49-61.
28. Torizuka T, Zasadny KR, Kison PV, Rommelfanger SG, Kaminski MS, Wahl RL. Metabolic response of non-Hodgkin's lymphoma to 131I-anti-B1 radioimmunotherapy: Evaluation with FDG PET. J Nucl Med 2000;41: 999-1005.
29. Chaise C, Itti E, Petegnief Y, Wirquin E, Copie-Bergman C, Farcet J-P, Delfau-Larue M-H, Meignan M, Talbot J-N, Molinier-Frenkel V. [F-18]- Fluoro-2-deoxy-D: -glucose positron emission tomography as a tool for early detection of immunotherapy response in a murine B cell lymphoma model. Cancer Immunol Immunother 2007;56: 1163-1171.
30. Gilles R, de Geus-Oei L-F, Mulders PFA, Oyen WJG. Immunotherapy response evaluation with (18)F-FDG-PET in patients with advanced stage renal cell carcinoma. World J Urol 2013;31: 841-846.
31. Nishikawa H, Sakaguchi S. Regulatory T cells in cancer immunotherapy. Curr Opin Immunol 2014;27: 1-7.
32. Tarhini AA, Edington H, Butterfield LH, Lin Y, Shuai Y, Tawbi H, Sander C, Yin Y, Holtzman M, Johnson J, et al. Immune monitoring of the circulation and the tumor microenvironment in patients with regionally advanced melanoma receiving neoadjuvant ipilimumab. PLoS One 2014;9: E87705.
33. Sterman DH, Recio A, Haas AR, Vachani A, Katz SI, Gillespie CT, Cheng G, Sun J, Moon E, Pereira L, et al. A phase I trial of repeated intrapleural adenoviral-mediated interferon-b gene transfer for mesothelioma and metastatic pleural effusions. Mol Ther 2010;18: 852-860.